Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alx Oncology Holdings Inc

NASDAQ: ALXO · Life Sciences · 3 alerts · CIK 1810182

Share price
$1.00Close, Nov 16
Market cap
$129M
Shares outstanding
129.27MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alx Oncology Holdings Inc filings on SEC EDGAR ↗

8:16 AM ET 10-Q
Financial Results

Alx Oncology Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Narrows

ALX Oncology reported a net loss of $57.7 million for the nine months ended September 30, 2026, an improvement from the $78.8 million loss in the prior year period. The company significantly strengthened its balance sheet through equity offerings, increasing total stockholders' equity to $125.9 million from $26.0 million at the end of 2025.

Key figure
Net loss $21.8M
8:11 AM ET 8-K
Financial Results

Alx Oncology Holdings Financial Results

ALX Oncology reported third quarter 2026 financial results, ending the period with $147.2 million in cash and investments, which is expected to fund operations through the first half of 2028. The company highlighted clinical progress for evorpacept and ALX2004, with topline data from the ASPEN-09-Breast trial now expected in the second half of 2027.

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials. The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.